array(40) {
  [0]=>
  string(4) "8908"
  ["article_id"]=>
  string(4) "8908"
  [1]=>
  string(77) "Ancient teeth from Peru hint now-extinct monkeys crossed Atlantic from Africa"
  ["article_title"]=>
  string(77) "Ancient teeth from Peru hint now-extinct monkeys crossed Atlantic from Africa"
  [2]=>
  string(150) "Four fossilized monkey teeth discovered deep in the Peruvian Amazon provide new evidence that more than one group of ancient primates journeyed across"
  ["short_description"]=>
  string(150) "Four fossilized monkey teeth discovered deep in the Peruvian Amazon provide new evidence that more than one group of ancient primates journeyed across"
  [3]=>
  string(443) "Four fossilized monkey teeth discovered deep in the Peruvian Amazon provide new evidence that more than one group of ancient primates journeyed across the Atlantic Ocean from Africa. The teeth are from a newly discovered species belonging to an extinct family of African primates known as parapithecids. Fossils discovered at the same site in Peru had earlier offered the first proof that South American monkeys evolved from African primates. "
  ["description"]=>
  string(443) "Four fossilized monkey teeth discovered deep in the Peruvian Amazon provide new evidence that more than one group of ancient primates journeyed across the Atlantic Ocean from Africa. The teeth are from a newly discovered species belonging to an extinct family of African primates known as parapithecids. Fossils discovered at the same site in Peru had earlier offered the first proof that South American monkeys evolved from African primates. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "34"
  ["rss_id"]=>
  string(2) "34"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409141528.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409141528.htm"
  [15]=>
  string(19) "2020-04-10 02:15:28"
  ["add_date"]=>
  string(19) "2020-04-10 02:15:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:11"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:11"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8877"
  ["article_id"]=>
  string(4) "8877"
  [1]=>
  string(49) "Scientists discover six new coronaviruses in bats"
  ["article_title"]=>
  string(49) "Scientists discover six new coronaviruses in bats"
  [2]=>
  string(150) "Researchers have discovered six new coronaviruses in bats in Myanmar -- the first time these viruses have been detected anywhere in the world. Future "
  ["short_description"]=>
  string(150) "Researchers have discovered six new coronaviruses in bats in Myanmar -- the first time these viruses have been detected anywhere in the world. Future "
  [3]=>
  string(266) "Researchers have discovered six new coronaviruses in bats in Myanmar -- the first time these viruses have been detected anywhere in the world. Future studies will evaluate the potential for transmission across species to better understand the risks to human health. "
  ["description"]=>
  string(266) "Researchers have discovered six new coronaviruses in bats in Myanmar -- the first time these viruses have been detected anywhere in the world. Future studies will evaluate the potential for transmission across species to better understand the risks to human health. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409141429.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409141429.htm"
  [15]=>
  string(19) "2020-04-10 02:14:29"
  ["add_date"]=>
  string(19) "2020-04-10 02:14:29"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:05"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8878"
  ["article_id"]=>
  string(4) "8878"
  [1]=>
  string(52) "Ear's inner secrets revealed with new technology"
  ["article_title"]=>
  string(52) "Ear's inner secrets revealed with new technology"
  [2]=>
  string(150) "What does it actually look like deep inside our ears? This has been very difficult to study as the inner ear is protected by the hardest bone in the b"
  ["short_description"]=>
  string(150) "What does it actually look like deep inside our ears? This has been very difficult to study as the inner ear is protected by the hardest bone in the b"
  [3]=>
  string(349) "What does it actually look like deep inside our ears? This has been very difficult to study as the inner ear is protected by the hardest bone in the body. But with the help of synchrotron X-rays, it is now possible to depict details inside the ear three-dimensionally. Researchers have now used the method to map the blood vessels of the inner ear. "
  ["description"]=>
  string(349) "What does it actually look like deep inside our ears? This has been very difficult to study as the inner ear is protected by the hardest bone in the body. But with the help of synchrotron X-rays, it is now possible to depict details inside the ear three-dimensionally. Researchers have now used the method to map the blood vessels of the inner ear. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409140031.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409140031.htm"
  [15]=>
  string(19) "2020-04-10 02:00:31"
  ["add_date"]=>
  string(19) "2020-04-10 02:00:31"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:05"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8879"
  ["article_id"]=>
  string(4) "8879"
  [1]=>
  string(66) "Identical mice, different gut bacteria, different levels of cancer"
  ["article_title"]=>
  string(66) "Identical mice, different gut bacteria, different levels of cancer"
  [2]=>
  string(150) "Some types of gut bacteria are better than others at stimulating certain immune cells, specifically CD8+ T cells. And while these CD8+ T cells normall"
  ["short_description"]=>
  string(150) "Some types of gut bacteria are better than others at stimulating certain immune cells, specifically CD8+ T cells. And while these CD8+ T cells normall"
  [3]=>
  string(347) "Some types of gut bacteria are better than others at stimulating certain immune cells, specifically CD8+ T cells. And while these CD8+ T cells normally help protect the body against cancer, overstimulating them may promote inflammation and exhaust the T cells -- which can actually increase susceptibility to cancer, according to new mouse model. "
  ["description"]=>
  string(347) "Some types of gut bacteria are better than others at stimulating certain immune cells, specifically CD8+ T cells. And while these CD8+ T cells normally help protect the body against cancer, overstimulating them may promote inflammation and exhaust the T cells -- which can actually increase susceptibility to cancer, according to new mouse model. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409140019.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409140019.htm"
  [15]=>
  string(19) "2020-04-10 02:00:19"
  ["add_date"]=>
  string(19) "2020-04-10 02:00:19"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:05"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8880"
  ["article_id"]=>
  string(4) "8880"
  [1]=>
  string(80) "Global trial fast tracks testing of hydroxychloroquine, other COVID-19 therapies"
  ["article_title"]=>
  string(80) "Global trial fast tracks testing of hydroxychloroquine, other COVID-19 therapies"
  [2]=>
  string(158) "A novel 'learning while doing' clinical trial approach called REMAP helps doctors find the optimal trade-off between quickly adopting new therapies du"
  ["short_description"]=>
  string(158) "A novel 'learning while doing' clinical trial approach called REMAP helps doctors find the optimal trade-off between quickly adopting new therapies du"
  [3]=>
  string(414) "A novel 'learning while doing' clinical trial approach called REMAP helps doctors find the optimal trade-off between quickly adopting new therapies during a pandemic, such as the anti-malarial drug hydroxychloroquine, and waiting until they are tested in longer clinical trials. The trial learns from similar trials enrolling around the world and uses artificial intelligence to quickly arrive at answers. "
  ["description"]=>
  string(414) "A novel 'learning while doing' clinical trial approach called REMAP helps doctors find the optimal trade-off between quickly adopting new therapies during a pandemic, such as the anti-malarial drug hydroxychloroquine, and waiting until they are tested in longer clinical trials. The trial learns from similar trials enrolling around the world and uses artificial intelligence to quickly arrive at answers. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409140015.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409140015.htm"
  [15]=>
  string(19) "2020-04-10 02:00:15"
  ["add_date"]=>
  string(19) "2020-04-10 02:00:15"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:05"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8979"
  ["article_id"]=>
  string(4) "8979"
  [1]=>
  string(80) "when should employers disclose food or fragrance restrictions to job candidates?"
  ["article_title"]=>
  string(80) "when should employers disclose food or fragrance restrictions to job candidates?"
  [2]=>
  string(150) "A reader writes: When during the interview process should an employer disclose that they have food or scent restrictions in their office? I know on th"
  ["short_description"]=>
  string(150) "A reader writes: When during the interview process should an employer disclose that they have food or scent restrictions in their office? I know on th"
  [3]=>
  string(1678) "
A reader writes: When during the interview process should an employer disclose that they have food or scent restrictions in their office? I know on the employee side you recommend waiting until you have an offer or have started the job, but as the employer when should they bring up that the office is nut-free […]
&#nl
&#nl
You may also like:
&#nl
&#nl
asking your office to ban fragrances in the workplace
&#nl
our group member has a fragrance sensitivity - and we're supposed to be hugged to check for any scents
&#nl
how much should we accommodate employees' dietary restrictions at work events?
&#nl
&#nl
&#nl
&#nl
when should employers disclose food or fragrance restrictions to job candidates? was originally published by Alison Green on Ask a Manager.
&#nl"
  ["description"]=>
  string(1678) "
A reader writes: When during the interview process should an employer disclose that they have food or scent restrictions in their office? I know on the employee side you recommend waiting until you have an offer or have started the job, but as the employer when should they bring up that the office is nut-free […]
&#nl
&#nl
You may also like:
&#nl
&#nl
asking your office to ban fragrances in the workplace
&#nl
our group member has a fragrance sensitivity - and we're supposed to be hugged to check for any scents
&#nl
how much should we accommodate employees' dietary restrictions at work events?
&#nl
&#nl
&#nl
&#nl
when should employers disclose food or fragrance restrictions to job candidates? was originally published by Alison Green on Ask a Manager.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "5"
  ["category"]=>
  string(1) "5"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "50"
  ["rss_id"]=>
  string(2) "50"
  [14]=>
  string(120) "https://www.askamanager.org/2020/04/when-should-employers-disclose-food-or-fragrance-restrictions-to-job-candidates.html"
  ["blog_url"]=>
  string(120) "https://www.askamanager.org/2020/04/when-should-employers-disclose-food-or-fragrance-restrictions-to-job-candidates.html"
  [15]=>
  string(19) "2020-04-10 01:59:02"
  ["add_date"]=>
  string(19) "2020-04-10 01:59:02"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:24"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8921"
  ["article_id"]=>
  string(4) "8921"
  [1]=>
  string(70) "Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month"
  ["article_title"]=>
  string(70) "Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month"
  [2]=>
  string(150) "Multiple COVID-19 vaccine candidates that use a new technology called messenger RNA are now being readied for clinical trials that Pfizer and BioNTech"
  ["short_description"]=>
  string(150) "Multiple COVID-19 vaccine candidates that use a new technology called messenger RNA are now being readied for clinical trials that Pfizer and BioNTech"
  [3]=>
  string(366) "Multiple COVID-19 vaccine candidates that use a new technology called messenger RNA are now being readied for clinical trials that Pfizer and BioNTech plan to start in coming weeks. The partnership pairs the mRNA vaccine technology of BioNTech (NASDAQ: BNTX) with the vaccine and clinical trial experience of Pfizer (NYSE: PFE). The companies said Thursday […]"
  ["description"]=>
  string(366) "Multiple COVID-19 vaccine candidates that use a new technology called messenger RNA are now being readied for clinical trials that Pfizer and BioNTech plan to start in coming weeks. The partnership pairs the mRNA vaccine technology of BioNTech (NASDAQ: BNTX) with the vaccine and clinical trial experience of Pfizer (NYSE: PFE). The companies said Thursday […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(110) "https://xconomy.com/national/2020/04/09/pfizer-biontech-say-mrna-covid-19-vaccine-trials-may-start-this-month/"
  ["blog_url"]=>
  string(110) "https://xconomy.com/national/2020/04/09/pfizer-biontech-say-mrna-covid-19-vaccine-trials-may-start-this-month/"
  [15]=>
  string(19) "2020-04-10 01:41:41"
  ["add_date"]=>
  string(19) "2020-04-10 01:41:41"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:12"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:12"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8995"
  ["article_id"]=>
  string(4) "8995"
  [1]=>
  string(62) "Indiana Network for Population Health tackles SDOH integration"
  ["article_title"]=>
  string(62) "Indiana Network for Population Health tackles SDOH integration"
  [2]=>
  string(151) "In HIMSS20 Digital, health informatics expert Brian Dixon links the power of health information exchange networks to actionable data for hospitals.&#nl"
  ["short_description"]=>
  string(151) "In HIMSS20 Digital, health informatics expert Brian Dixon links the power of health information exchange networks to actionable data for hospitals.&#nl"
  [3]=>
  string(151) "In HIMSS20 Digital, health informatics expert Brian Dixon links the power of health information exchange networks to actionable data for hospitals.&#nl"
  ["description"]=>
  string(151) "In HIMSS20 Digital, health informatics expert Brian Dixon links the power of health information exchange networks to actionable data for hospitals.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(96) "https://www.healthcareitnews.com/news/indiana-network-population-health-tackles-sdoh-integration"
  ["blog_url"]=>
  string(96) "https://www.healthcareitnews.com/news/indiana-network-population-health-tackles-sdoh-integration"
  [15]=>
  string(19) "2020-04-10 01:13:51"
  ["add_date"]=>
  string(19) "2020-04-10 01:13:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:28"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8980"
  ["article_id"]=>
  string(4) "8980"
  [1]=>
  string(48) "my resigning employee is spreading lies about me"
  ["article_title"]=>
  string(48) "my resigning employee is spreading lies about me"
  [2]=>
  string(150) "A reader writes: I manage a large medical practice. One of my leads gave her notice about two weeks ago. At the time, we congratulated her because she"
  ["short_description"]=>
  string(150) "A reader writes: I manage a large medical practice. One of my leads gave her notice about two weeks ago. At the time, we congratulated her because she"
  [3]=>
  string(1514) "
A reader writes: I manage a large medical practice. One of my leads gave her notice about two weeks ago. At the time, we congratulated her because she has gone through some rough times lately and we were excited that a new job would give her a new outlook, plus a nice raise. She told […]
&#nl
&#nl
You may also like:
&#nl
&#nl
my employee lies and says other people's work is her own
&#nl
our horrible HR manager tells lies, is rude and petty, and won't do her job
&#nl
my employee announced she's leaving but doesn't know when
&#nl
&#nl
&#nl
&#nl
my resigning employee is spreading lies about me was originally published by Alison Green on Ask a Manager.
&#nl"
  ["description"]=>
  string(1514) "
A reader writes: I manage a large medical practice. One of my leads gave her notice about two weeks ago. At the time, we congratulated her because she has gone through some rough times lately and we were excited that a new job would give her a new outlook, plus a nice raise. She told […]
&#nl
&#nl
You may also like:
&#nl
&#nl
my employee lies and says other people's work is her own
&#nl
our horrible HR manager tells lies, is rude and petty, and won't do her job
&#nl
my employee announced she's leaving but doesn't know when
&#nl
&#nl
&#nl
&#nl
my resigning employee is spreading lies about me was originally published by Alison Green on Ask a Manager.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "5"
  ["category"]=>
  string(1) "5"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "50"
  ["rss_id"]=>
  string(2) "50"
  [14]=>
  string(89) "https://www.askamanager.org/2020/04/my-resigning-employee-is-spreading-lies-about-me.html"
  ["blog_url"]=>
  string(89) "https://www.askamanager.org/2020/04/my-resigning-employee-is-spreading-lies-about-me.html"
  [15]=>
  string(19) "2020-04-10 00:29:55"
  ["add_date"]=>
  string(19) "2020-04-10 00:29:55"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:24"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8763"
  ["article_id"]=>
  string(4) "8763"
  [1]=>
  string(67) "Boris Johnson Moved Out of ICU, But Still in Hospital With COVID-19"
  ["article_title"]=>
  string(67) "Boris Johnson Moved Out of ICU, But Still in Hospital With COVID-19"
  [2]=>
  string(150) "TUESDAY, April 7, 2020 -- British Prime Minister Boris Johnsonhas been taken out of intensive care at the London hospital where he has been treated fo"
  ["short_description"]=>
  string(150) "TUESDAY, April 7, 2020 -- British Prime Minister Boris Johnsonhas been taken out of intensive care at the London hospital where he has been treated fo"
  [3]=>
  string(252) "TUESDAY, April 7, 2020 -- British Prime Minister Boris Johnsonhas been taken out of intensive care at the London hospital where he has been treated for COVID-19, a Downing Street spokesman said Thursday.&#nlJohnson, 55, remains hospitalized however,..."
  ["description"]=>
  string(252) "TUESDAY, April 7, 2020 -- British Prime Minister Boris Johnsonhas been taken out of intensive care at the London hospital where he has been treated for COVID-19, a Downing Street spokesman said Thursday.&#nlJohnson, 55, remains hospitalized however,..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "5"
  ["rss_id"]=>
  string(1) "5"
  [14]=>
  string(206) "https://www.drugs.com/news/boris-johnson-moved-out-icu-but-still-hospital-covid-19-89517.html?utm_source=ddc&utm_medium=rss&utm_campaign=Boris+Johnson+Moved+Out+of+ICU%2C+But+Still+in+Hospital+With+COVID-19"
  ["blog_url"]=>
  string(206) "https://www.drugs.com/news/boris-johnson-moved-out-icu-but-still-hospital-covid-19-89517.html?utm_source=ddc&utm_medium=rss&utm_campaign=Boris+Johnson+Moved+Out+of+ICU%2C+But+Still+in+Hospital+With+COVID-19"
  [15]=>
  string(19) "2020-04-10 00:04:43"
  ["add_date"]=>
  string(19) "2020-04-10 00:04:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:36:37"
  ["create_at"]=>
  string(19) "2020-04-12 16:36:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8932"
  ["article_id"]=>
  string(4) "8932"
  [1]=>
  string(70) "Viveve Could Hit Reset Button After Failing to Meet Endpoints in Trial"
  ["article_title"]=>
  string(70) "Viveve Could Hit Reset Button After Failing to Meet Endpoints in Trial"
  [2]=>
  string(153) "&#nlViveve Medical has hit a snag after it failed to meet the endpoints in a clinical trial for technology to improve the sexual function in women follow"
  ["short_description"]=>
  string(153) "&#nlViveve Medical has hit a snag after it failed to meet the endpoints in a clinical trial for technology to improve the sexual function in women follow"
  [3]=>
  string(2817) "&#nl
Viveve Medical has hit a snag after it failed to meet the endpoints in a clinical trial for technology to improve the sexual function in women following vaginal childbirth.
&#nl
The Englewood, CO-based company said as a result of the results and impact from the COVID-19 pandemic that it was evaluating strategic alternatives, as well as actively assessing its current organization and cost structure.
&#nl
Viveve is developing a Cryogen-cooled Monopolar Radiofrequency (CMRF) technology that can treat vaginal laxity. The technology delivers RF energy deeply into soft tissues – which results in neocollagenesis, or a straightening or tightening of the skin.
&#nl
In a Securities and Exchange Commission filing, the company said the VIVEVE II study did not meet its primary endpoint of demonstrating a statistically significant improvement in the mean change from baseline in total Female Sexual Function Index (FSFI) score at 12 months. The study included 220 subjects that completed 12-month follow-up. Subjects were randomized in a 1:1 ratio for the active (N=114) and the sham (N=106) treatments at 17 clinical sites in the U.S.
&#nl
The adjusted mean change for the active group was 9.8 and the adjusted mean change for the sham group was 9.0, a difference of 0.8 (p=0.3942). There were no serious device-related adverse events reported. The treatment groups were well balanced, and the number of subjects lost to follow-up was as expected.
&#nl
"We are extremely disappointed that the VIVEVE II trial did not achieve its primary endpoint. Although there was substantial improvement in the total FSFI score from baseline to the final 12-month follow-up in the active group, indicating a significant treatment effect, there was not sufficient separation from the sham group to achieve statistical significance," said Scott Durbin, CEO of Viveve, said in a release. "We intend to thoroughly analyze the complete data set, including all secondary and exploratory endpoints to better understand this outcome.
&#nl
In August of 2018, Viveve won a nod from FDA to continue enrollment in the trial. The company had also submitted an IDE application to FDA to get authorization for a device to treat stress urinary incontinence (SUI).
&#nl
 
"
  ["description"]=>
  string(2817) "&#nl
Viveve Medical has hit a snag after it failed to meet the endpoints in a clinical trial for technology to improve the sexual function in women following vaginal childbirth.
&#nl
The Englewood, CO-based company said as a result of the results and impact from the COVID-19 pandemic that it was evaluating strategic alternatives, as well as actively assessing its current organization and cost structure.
&#nl
Viveve is developing a Cryogen-cooled Monopolar Radiofrequency (CMRF) technology that can treat vaginal laxity. The technology delivers RF energy deeply into soft tissues – which results in neocollagenesis, or a straightening or tightening of the skin.
&#nl
In a Securities and Exchange Commission filing, the company said the VIVEVE II study did not meet its primary endpoint of demonstrating a statistically significant improvement in the mean change from baseline in total Female Sexual Function Index (FSFI) score at 12 months. The study included 220 subjects that completed 12-month follow-up. Subjects were randomized in a 1:1 ratio for the active (N=114) and the sham (N=106) treatments at 17 clinical sites in the U.S.
&#nl
The adjusted mean change for the active group was 9.8 and the adjusted mean change for the sham group was 9.0, a difference of 0.8 (p=0.3942). There were no serious device-related adverse events reported. The treatment groups were well balanced, and the number of subjects lost to follow-up was as expected.
&#nl
"We are extremely disappointed that the VIVEVE II trial did not achieve its primary endpoint. Although there was substantial improvement in the total FSFI score from baseline to the final 12-month follow-up in the active group, indicating a significant treatment effect, there was not sufficient separation from the sham group to achieve statistical significance," said Scott Durbin, CEO of Viveve, said in a release. "We intend to thoroughly analyze the complete data set, including all secondary and exploratory endpoints to better understand this outcome.
&#nl
In August of 2018, Viveve won a nod from FDA to continue enrollment in the trial. The company had also submitted an IDE application to FDA to get authorization for a device to treat stress urinary incontinence (SUI).
&#nl
 
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "40"
  ["rss_id"]=>
  string(2) "40"
  [14]=>
  string(91) "https://www.mddionline.com/viveve-could-hit-reset-button-after-failing-meet-endpoints-trial"
  ["blog_url"]=>
  string(91) "https://www.mddionline.com/viveve-could-hit-reset-button-after-failing-meet-endpoints-trial"
  [15]=>
  string(19) "2020-04-09 23:52:49"
  ["add_date"]=>
  string(19) "2020-04-09 23:52:49"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:20"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:20"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8881"
  ["article_id"]=>
  string(4) "8881"
  [1]=>
  string(80) "Optical imaging technology may help surgeons better treat cancer, brain diseases"
  ["article_title"]=>
  string(80) "Optical imaging technology may help surgeons better treat cancer, brain diseases"
  [2]=>
  string(150) "Researchers created technology that uses optical imaging to better help surgeons map out tumors in the body and help them understand how certain disea"
  ["short_description"]=>
  string(150) "Researchers created technology that uses optical imaging to better help surgeons map out tumors in the body and help them understand how certain disea"
  [3]=>
  string(184) "Researchers created technology that uses optical imaging to better help surgeons map out tumors in the body and help them understand how certain diseases affect activity in the brain. "
  ["description"]=>
  string(184) "Researchers created technology that uses optical imaging to better help surgeons map out tumors in the body and help them understand how certain diseases affect activity in the brain. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409113127.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2020/04/200409113127.htm"
  [15]=>
  string(19) "2020-04-09 23:31:27"
  ["add_date"]=>
  string(19) "2020-04-09 23:31:27"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:05"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:05"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}